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The role of endogenous galectin-1 (Gal-1) in acute
inflammation has been poorly investigated. We there-
fore performed the carrageenan-induced paw edema
model in wild-type and Gal-1/ mice. On subplantar
injection of carrageenan, Gal-1/ mice displayed a
similar first phase of edema (<24 hours) to wild-type
mice; however, a much less pronounced second
phase (48 to 96 hours) was evident in this genotype.
This reduced inflammation was associated with lower
paw expression of inflammatory genes and cell infil-
trates. Analysis of galectin protein and mRNA expres-
sion revealed high expression of Gal-1 in wild-type
paws during resolution (>48 hours), with some ex-
pression of galectin-9 (Gal-9). Administration of sta-
ble Gal-1 to wild-type mice completely ablated the
first phase of edema but was ineffective when admin-
istered therapeutically at the 24-hour time point. Con-
versely, Gal-9 administration did not alter the first
phase of edema but significantly reduced the second
phase when administered therapeutically. This sug-
gests anti-inflammatory actions for both proteins in
this model albeit at different phases of the inflamma-
tory response. Collectively, these data indicate that
the absence of endogenous Gal-1 results in an abro-
gated response during the second phase of the
edema reaction. (Am J Pathol 2011, 178:1201–1209; DOI:
10.1016/j.ajpath.2010.11.073)
The process of leukocyte egress from the blood stream
toward the site of tissue injury or infection is a life-saving
process that is fundamental to survival of the host. Hence, it
is governed by a series of cellular responses, the result ofseveral fine-tuned molecular events, which assure the mi-
gration of the right type of leukocytes, in the correct vascular
bed, ready to attack and dispose of the inflammatory insult.1
However, this response can potentially be disruptive due to
the dangerous factors (reactive oxygen species and en-
zymes) released from emigrated white blood cells (eg,
PMN) such that several mechanisms are activated in the
host, not only to wall off production of lethal factors, but also
to control the time- and spatial-dependency of the process
of migration.2 Moreover, the life span of the emigrated leu-
kocyte is also tightly regulated promoting safe/programmed
cell death and removal.3 Therefore, besides classes of pro-
inflammatory mediators and factors (eg, adhesion mole-
cules) there exists an equally ever increasing list of en-
dogenous anti-inflammatory mediators that promote the
resolution of inflammation.2,4,5
Galectin-1 (Gal-1) is emerging as one of these effectors
of endogenous anti-inflammation. In brief, several studies
have indicated the inhibitory properties of Gal-1 on T cells,
through its ability to induce apoptosis via interactions with
several cell-surface glycoprotein receptors including CD7,
CD2, CD43, and CD45.6–8 In the context of innate immu-
nity, Gal-1 inhibits PMN chemotaxis,9 promotes phosphati-
dylserine (PS) exposure and subsequent phagocytosis of
activated human neutrophils10 and reduces PMN interac-
tion with endothelial cell monolayers.11 More importantly,
pharmacological administration of Gal-1 inhibits several
facets of acute inflammation including edema formation12
and tissue recovery of infiltrated PMN.9 However, not
many studies have investigated the role of endogenous
Gal-1 on specific aspects of the innate immune response.
Supported by a BBSRC-CASE PhD Studentship and by an Arthritis Re-
search UK fellowship (18103) (D.C.). This work forms part of the research
themes contributing to the translational research portfolio of Barts and the
London Cardiovascular Biomedical Research Unit, which is supported
and funded by the National Institute of Health Research.
Accepted for publication November 23, 2010.
Current address of F.M., University of Naples “Federico II”, Naples,
Italy; of A.L.F.S., Ensino e Inovação, CTM - Far-Manguinhos, Brazil.
Address reprint requests to Dianne Cooper, B.Sc., M.Sc., Ph.D., or Mauro
Perretti, Ph.D., William Harvey Research Institute, Barts and The London
School of Medicine, QueenMary University of London, Charterhouse Square,
London EC1M 6BQ, United Kingdom. E-mail: d.cooper@qmul.ac.uk or
m.perretti@qmul.ac.uk.
1201
1202 Iqbal et al
AJP March 2011, Vol. 178, No. 3For instance, Gal-1/ mice displayed increased levels
of leukocyte recruitment in a model of peritonitis (http://
www.functionalglycomics.org/) and increased vascular
events such as leukocyte adhesion and emigration in the
inflamed cremasteric microcirculation.11
Gal-1 is not the only galectin endowed with anti-inflam-
matory activities.13 Recent work has indicated Gal-9 as a
novel and potent anti-inflammatory protein, largely due to
its ability to induce T-cell apoptosis in models of experi-
mental allergic encephalomyelitis14 and nephritis15 and
inhibition of T-cell infiltration in a murine model of mite
allergen-induced asthma.16 Moreover, Gal-9/mice de-
velop spontaneous episodes of inflammatory arthritis and
administration of this protein exerts inhibitory properties
during the active phases of the collagen-induced arthritis
model.17,18 PMN has also been identified as a target cell
for Gal-9: in a murine model of the Schwartzman reaction,
neutropenic mice were no longer protected by adminis-
tration of recombinant Gal-9.19
The present study was undertaken to further our knowl-
edge on the role of endogenous Gal-1 on themultiple facets
of the inflammatory response, and the mouse carrageenan
(CG) paw edema model was applied to Gal-1/ mice. In
the mouse paw, injection of CG elicits a complex and long-
lasting response (compared to the more widely used rat
edemamodel which lasts essentially 24 hours20) character-
ized by an acute (24 hours) and a delayed (24 hours)
phase, with edema formation, marked influx of PMN, and
the involvement of several mediators.21,22
Materials and Methods
Animals
Male C57BL/6J (WT) and Gal-1/ mice were obtained
from B&K (Hull, UK). Original breeding pairs of Gal-
1/ (Lgals1 null) animals were generously provided
by the Consortium for Functional Glycomics (http://
www.functionalglycomics.org). In all cases, animals (6–8
weeks old) were used 7 days after arrival according to
guidelines laid down by the Local Ethical Committee for the
use of Animals (Barts and The London School of Medicine).
Moreover, animal work was performed according to Home
Office regulations (Guidance on the Operation of Animals,
Scientific Procedures Act, 1986).
Stable Forms of Gal-1 and Gal-9
We were kindly provided with stable forms of Gal-1
(sGal-1) and Gal-9 (sGal-9) from GalPharma (Takamatsu,
Kagawa, Japan). Details relating to the generation, struc-
ture, and function of both sGal-1 and -9 can be found in
previous reports.23,24 Briefly, Gal-1 is highly susceptible
to oxidation, specifically at its cysteine residues, which
renders the molecule inactive. sGal-1 is a cysteine-less
mutant of Gal-1 which is resistant to oxidation and retains
all of the known activities of WT Gal-1. In the case of Gal-9
it is highly susceptible to proteolytic degradation at the
linker peptide. sGal-9 is a linker-less mutant of Gal-9
which is resistant to proteolytic degradation and again
retains all known activities of WT Gal-9.CG Model of Paw Edema
Paw edema was induced as previously described.21,25,26
Briefly, animals received a subplantar (s.pl) injection of
50 l carrageenan (lambda species) 1% (w/v) in saline
into the right paw with an equivalent volume of saline
administered to the contralateral paw used as control.
Paw volume was measured with a hydro-plethysmometer
with mice paw adaptors (Ugo Basile, Milan, Italy) imme-
diately before subplantar injection and up to 144 hours
thereafter. Changes in paw volume were calculated by
subtracting the paw volume of CG and saline (control) in-
jected paws at each time point. Several experiments were
conducted comparing responses inWT andGal-1/mice.
To assess the effects of the exogenous protein, three dif-
ferent regimes were followed: i) sGal-1 or sGal-9 (generous
gifts of GalPharma, Takamatsu, Kagawa, Japan) were co-
administered with CG, ii) administration of sGal-1 or sGal-9
intravenously (tail vein) 30 minutes before CG, and iii) ad-
ministration of sGal-1 or sGal-9 intravenously (tail vein) 24
hours after induction with CG.
Cellular and Biochemical Analyses
RNA Isolation and cDNA Synthesis
Mice were euthanized at selected time points by
cervical dislocation and paws harvested. RNA isolation
was performed; briefly, paws were cut and added to
pre-weighed tubes containing ceramic beads (Stretton
Scientific, Cepheid, Derbyshire, UK). Samples were
weighed and a single volume of TRI reagent (1 ml TRI
reagent/50–100 mg tissue) (Ambion, Warrington, UK)
was added, followed by homogenization with the Bertin
homogenizer (Bertin Technologies, Bordeaux, France)
using the following parameters: four cycles at 6500 rpm
for 30 seconds. Samples were centrifuged at 10,500 rpm
for 2 minutes; supernatants were transferred to new tubes
and subsequent steps were performed according to the
manufacturers’ guidelines to isolate the RNA. To remove
all contaminating genomic DNA, the isolated RNA under-
went treatment with TURBO DNase free kit (Ambion) fol-
lowing the manufacturer’s “vigorous treatment” protocol.
The concentration and purity of the RNA was analyzed
using the Nanodrop ND-1000 (NanoDrop Technologies,
Wilmington, DE). First strand cDNA synthesis was per-
formed with the Superscript III reverse transcriptase sys-
tem (Invitrogen, Carlsbad, CA) following the manufactur-
er’s protocol on a total of 2.5 g of RNA.
Real-Time PCR
Real-time PCR was performed with the ABI Prism 7900
Real-time PCR system (Applied Biosystems Inc, Foster
City, CA). A standard thermal cycling amplification profile
was applied: 95°C for 15 minutes; 35 cycles–94°C for 15
seconds, 55°C for 30 seconds, and 72°C for 30 seconds
followed by a melt curve analysis. For each reaction, a
total volume of 10 l was used, which consisted of 2 l of
diluted cDNA (20 ng/l), 5.2 l of 1X Power SYBR Green
mastermix (Applied Biosystems), 1 l of gene specific
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mRNA data were normalized relative to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and then
used to calculate expression levels. The comparative
cycle threshold (Ct) method was used to measure the
gene transcription in samples.27 The results are ex-
pressed as relative units based on calculation of
2DDCt, which gives the relative amount of target gene
normalized to endogenous control (GAPDH) and to the
control (naïve) sample with the expression set as 1.
MPO Assay
The edema response was monitored for 12 hours, with
some paws harvested at 4 hours for an MPO assay,
which was performed as previously described.28
Western Blotting
Briefly, paws were perforated several times with a 19G
needle followed by centrifugation at 5000 rpm for 5 min-
utes. Exudates were collected and a BCA protein assay
performed. Protein levels were equalized and 6 hot
sample buffer was added. Exudates were analyzed by
standard SDS-PAGE and proteins transferred to PVDF
membranes (Millipore, Watford, UK). Membranes were
probed for galectin-1 (polyclonal goat anti-mouse galec-
tin-1; 1:1000 dilution) or galectin-9 (polyclonal goat anti-
mouse galectin-9; 1:1000 dilution) (R&D Systems, Abing-
don, UK). Primary antibodies were diluted with 1% nonfat
dried milk (w/v) made up in TBS containing 0.1%
Tween20 and incubated with membranes overnight.
Membranes underwent three 5-minute washes with
TBS-T and were incubated with HRP-conjugated rabbit
anti-goat (Dako, Cambridge, UK), and proteins were de-
tected with enhanced chemiluminescence visualized on
hyperfilm (GE Health Care, Little Chalfont, UK).
Histology and Immunohistochemistry
Paws were harvested from mice and fixed for 48 hours
with 4% paraformaldehyde, decalcified in 4% EDTA for
21 days, and embedded in paraffin and 5-m sections
were cut and stained with H&E (Sigma-Aldrich, Gilling-
ham, Dorset, UK). Specific immunostaining was per-
formed on sections for Gal-1, Gal-9, and cleaved
caspase-3. Briefly, paraffin sections were deparaffinized,
followed by antigen retrieval with citrate buffered retrieval
solution (Dako, Glostup, Denmark) for 10 minutes at
95°C. Endogenous avidin and biotin activity was blocked
with a commercially available kit from Dako followed by
incubation with serum-free protein block (Dako). Sections
were then incubated with either polyclonal goat-anti-
mouse galectin-1, polyclonal goat-anti-mouse galectin-9,
or polyclonal rabbit anti-cleaved caspase-3 for 1 hour at
RT. Sections were washed with TBS then incubated with
rabbit-anti-goat biotin (1:100) or sheep-anti-rabbit biotin
(1:100) (Dako) for 30 minutes at RT, followed by amplifi-
cation with the Vectastain elite ABC kit (Vector Laborato-
ries, Peterborough, UK). Sections were developed using
DAB substrate kit (Dako), counterstained with hematox-ylin, and mounted with DPX (VWR, Leicestershire, UK). In
some sets of experiments, double immunofluorescence
staining with anti-CD3 (Dako) and cleaved caspase-3
was performed and carried out as described above. In
this instance secondary antibodies were conjugated to
either an Alexa 488 or 555. DAPI (1:1000) (Dako) was
used as a counterstain for cell nuclei. All primary and
secondary antibodies were diluted in Dako antibody dil-
uent. In all cases, a minimum 3 sections per animal
were evaluated. Digital images were taken using Image
Pro image analysis software (Media Cybernetics, Wok-
ingham, Berkshire, UK).
The quantification of caspase-3 positive cells was car-
ried out in a double-blinded manner. Six visual fields of
the paw sections were counted at a 20 magnification.
Two sections per paw were evaluated with the percent-
age of caspase-3 positive cells calculated from the total
cell infiltrate per field.
Flow Cytometric Analysis
Cells recovered from the paws were washed with PBS
and re-suspended in FACS buffer (PBS supplemented
with 0.1% NaN3, 10% rat serum) containing CD16/CD32
FcIIR blocking antibody (clone 93; eBioscience, Wem-
bley, UK) for 30 minutes at 4°C. Specific leukocyte pop-
ulations were identified by single or double staining with
the following monoclonal conjugated antibodies; PE-con-
jugated rat-anti-mouse CD11b (Clone: M1/70.15; AbD
Serotec, Kidlington, Oxford, UK), FITC-conjugated anti-
mouse F4/80 (Clone Cl:A3-1; AbD Serotec), FITC-conju-
gated anti-mouse Ly6G (Gr1) (Clone RB6-8C5; eBiosci-
ence), PE-conjugated anti-mouse CCR7 (Clone 4B12;
eBioscience), CY5-conjugated anti-mouse CD11c (Clone
N418, eBioscience), and isotype controls (eBR2a, eBio-
science) for 1 hour at 4°C. Cell populations were ana-
lyzed with FACScalibur flow cytometry using CellQuest
software (BD Bioscience, Oxford, UK). A minimum of
10,000 events were acquired, with the percentage total
events in each population compared to the total cell
count to calculate the specific cell infiltrate per paw.
Statistical Tests
All data are reported as mean  SEM of n observations,
using at least three mice per group. Statistical evaluation
was performed using one-way analysis of variance (anal-
ysis of variance) (Prism4 GraphPad Software, San Diego,
CA) followed by Bonferroni test for posthoc analyses,
taking a probability P  0.05 as significant. Where two
variables were analyzed, a Student’s t-test was used.
Results
Exogenous and Endogenous Gal-1 in the Paw
Edema Model
Before testing the potential role of endogenous Gal-1 in
the CG-induced edema model, we determined how sus-
ceptible this inflammatory response was to the exoge-
1204 Iqbal et al
AJP March 2011, Vol. 178, No. 3nous application of sGal-1. Treatment of mice with sGal-1
led to a complete ablation of the first phase of the edema
response (Figure 1A) irrespective of whether it was ad-
ministered intravenously as a pretreatment or co-injected
into the paw with the CG. No effect was observed on the
second phase of edema. In line with previous studies,9,11
the administration of exogenous sGal-1 also resulted in a
reduced neutrophil recruitment, as assessed by quanti-
fying myeloperoxidase activity at the 4-hour time point
(Figure 1B).
We then compared the edema response in WT and Gal-
1/mice throughout the full time course of this model.21,22
Injection of CG provoked an initial peak of edema (6–8
hours post-CG) followed by a delayed phase between the
48- and 96-hour time points (Figure 2A). In Gal-1/ mice,
the first phase followed the profile of WT mice; how-
ever, a blunted response was observed for the second
phase with significantly lower edema values at 72
hours and 96 hours post-CG (Figure 2A). The extent of
tissue pathology in the two genotypes is shown in
representative images in Figure 2B (96-hour time
point).
The contrasting degree of edema observed in the
Gal-1/ mice at later time points instructed the next
set of experiments where cell infiltrate and inflamma-
tory mediator expression in the paw were determined.
Table 1 reports the recovery of PMN (Gr1ve cells), den-
dritic cells (CCR7 and CD11c double positive cells), and
mono-macrophages (F4/80ve cells). Whereas the injection
of CG incremented the recovery of all three of these cell
types at both 48 and 96 hours, absence of endogenous
Gal-1 affected predominantly the number of PMN, with over
50% reduction being measured 48 hours post-CG. A trend
toward an attenuation of both dendritic cell and macro-
phage infiltration was also evident at this time point,
whereas no variation between genotype was detected at 96
hours post-CG (Table 1).
Next, we measured gene expression of specific media-
tors in inflamed paw samples (96 hours post-GC). Absence
Figure 1. Gal-1 displays anti-inflammatory effects in the CG-induced paw
edema model. A: sGal-1 (3 g equivalent to 214 pmol) was either given
intravenously (i.v.) 30 minutes before CG, or co-administered with CG sub-
plantar (s.pl) into the right paw. An equal volume of saline was given s.pl
into the left paw and the edema profile was monitored for 96 hours. Paw
volume was assessed by plethysmography and edema calculated as the
difference between CG and PBS injected paws. Data are expressed as
mean  SEM of six mice per treatment. *P  0.05, **P  0.01, as compared
to WT (CG alone). B: Myeloperoxidase activity of paw tissue homogenates
obtained 4 hours after injection with CG alone, CGGal-1, or PBS alone.
Values are expressed as optical density units per mg of protein. Data are
expressed as mean SEM of three mice per treatment. *P 0.05, **P 0.01,
as compared to WT (CG alone).of endogenous Gal-1 produced selective alterations suchthat both IL/1 mRNA and inductible nitric oxide synthase
(iNOS) mRNA expression were markedly reduced in Gal-
1/ mice (Table 2) whereas no significant effect was ob-
served for TNF-, IL-6, and IL-10 mRNA. Interestingly,
TGF mRNA was augmented in Gal-1/ paws as com-
pared to WT.
Collectively, these unexpected results (reduced in-
flammatory response in Gal-1/ mice) prompted the
next set of experiments where expression of specific
galectins was monitored.
Galectin Expression in Inflamed Paws
Gene product for Gal-1, Gal-3, and Gal-9 was modulated
by the inflammatory response provoked by CG as mea-
sured in the whole paws collected from WT mice. Levels
of mRNA for Gal-1 were found to be higher basally in the
paw than was observed for Gal-3 and Gal-9 (Ct values of
20.80  0.98, 27.48  1.26, and 29.28  1.10 for Lgals1,
Lgals3, and Lgals9, respectively). Figure 3A shows that
Gal-1 message increases in the inflamed paw at 48 and
96 hours post-CG, as compared to non-inflamed paws.
Clearly no signal for Gal-1 message was observed in
Gal-1/ mice. The message for Gal-3 was delayed in its
modulation, with no difference between genotypes (Fig-
ure 3B). In contrast, interesting observations were made
for Gal-9 mRNA; in WT mice, Gal-9 mRNA increased
steadily from the 24- to 96-hour time point, reaching at the
later stage the highest degree of modulation as com-
pared to the other galectins (approximately 40-fold in-
crease) (Figure 3C). In Gal-1/ mice, Gal-9 mRNA was
already markedly elevated at the 24-hour time point and
reached its peak at 48 hours post CG (Figure 3C).
Changes in Gal-1 and Gal-9 mRNA were then followed
by analysis of protein expression in the inflamed paws of
WT and Gal-1/ mice. Fewer infiltrated cells were ap-
parent in the Gal-1/ mice compared to WT; of these
cells, the degree of immunoreactivity against Gal-9 was
comparable in both phenotypes (Figures 3E–F). A similar
pattern of Gal-9 protein expression was also detected by
Western blotting with comparable levels of Gal-9 ob-
served at 48 hours post-CG in both WT and Gal-1/ paw
exudates (Figure 3J). Three isoforms of Gal-9 are known
Figure 2. CG-induced paw edema profile in WT and Gal-1/mice. A: Paw
edema was induced by s.pl injection of 1% lambda CG (50l) into the right hind
paw of WT (black) and Gal-1/ (white) mice. The left hind paw received the
same volume of saline. Paw volume was assessed by plethysmography and
edema calculated as the difference between CG and saline treated paws. Data
are expressed as mean  SEM of n  15–25 mice per group. *P  0.05, **P 
0.01, ***P  0.001 as compared to WT. B: Representative images of edema
development in CG- (left) versus PBS-treated (right) paws from 48 hours time
point in WT and Gal-1/ mice.
d to Ga
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peptide that connects the two CRDs,29 while two isoforms
have been identified to date in mice.30 As seen in Figure
3J, only one isoform of Gal-9 was detected within paw
exudates at 24 and 48 hours while two isoforms were
present at 96 hours. Gal-1 protein was also markedly
expressed in the paws of WT mice with large amounts
recovered both at 24, 48, and even more at 96 hours post
CG (Figure 3J), a time point when resolution begins in WT
animals (see Figure 2). When compared to Gal-9 the level
of Gal-1 protein detected in both exudates and tissue
was far greater with the peak in expression in paw exu-
dates coinciding with the onset of resolution in WT mice.
Effect of Pharmacological Administration of
sGal-9
The mRNA data prompted us to test the effect of exog-
enously administered sGal-9 in the last part of the study.
Injection of different doses of sGal-9 intravenously 30
minutes before CG did not significantly reduce the first
phase of edema (Figure 4A). Similarly, this early pharma-
cological treatment with sGal-9 did not affect the second
phase of the edema response.
Therefore, we next administered sGal-9 according to a
therapeutic protocol, that is, 24 hours post-CG injection.
This time point was chosen as it precedes the beginning
of the bifurcation of the profile of the response between
Table 1. Characterization of Cellular Infiltrate in CG-Treated Paw
Marker Time (hours)
C
(1 
GR-1/CD11b 48 0.29
96 0.16
CD11c/CCR7 48 0.04
96 0.07
F4/80 48 0.25
96 0.22
Flow cytometry was performed on cells recovered from CG treated paw
mice per group). Double and single staining was carried out for Gr1/CD
expressed as mean  SEM.
*P  0.05 as compared to WT naïve (control), †P  0.05 as compare
Table 2. Cytokine mRNA Expression from CG-Treated Paws of
WT and Gal-1/ Mice
Cytokine
WT
(relative expression)
Gal-1/
(relative expression)
IL-1 320  61.79‡ 23.47  6.09
TNF- 37.46  7.03‡ 23.58  6.28*
IL-6 41.5  15.27 13.17  3.40
iNOS 103.64  27†¶ 5.47  1.57
IL-10 34.04  7.05† 44.98  7.67‡
TGF- 12.21  6.08* 25.47  2.60‡**
Real-time PCR analysis for TNF-, IL-1, IL-6, iNOS, IL-10, and TGF-
mRNA levels was performed on CG-treated paws of WT and Gal-1/
mice collected at the 96-hour time-point. Data are expressed as mean 
SEM (8 per group).
§P  0.05,
*P  0.05, †P  0.01, ‡P  0.001 as compared to control (WT Naïve),
¶  /P 0.01, P 0.001 as compared to Gal-1 , **P 0.01 as compared
to WT.WT and Gal-1/ mice (see Figure 2) and coincided also
with the initial upregulation (between 8- and 10-fold) of
Gal-9 mRNA measured in Gal-1/ paw extracts (Figure
3C). When given according to this therapeutic protocol,
sGal-9 blocked the edema response in WT mice so that
no further increments were measured up to 96 hours
(Figure 4B). This remarkable anti-inflammatory activity of
T and Gal-1/ Mice
w)
WT
(1  105/paw)
Gal-1/
(1  105/paw)
5 9.72  1.43*† 4.25  1.23*
2 0.53  0.18 0.64  0.10
1 1.21  0.24* 0.74  0.15*
3 5.95  1.64 5.17  2.21
2 3.7  0.40* 2.31  0.51*
4 3.2  1.41 2.29  0.72
and Gal-1/mice at 48 hours (five mice per group) and 96 hours (three
N), CD11c/CCR7 (migrating DC) and F4/80 (monocyte/ MØ). Data are
l-1/.
Figure 3. Galectin-mRNA expression profile in CG treated paws of WT and
Gal-1/mice. Real-time PCR analysis for Gal-1 (A), Gal-3 (B), and Gal-9 (C)
mRNA levels were assessed in CG-treated paws of WT (black circle) and
Gal-1/ (white circle) mice collected 6, 24, 48, 96 hours post-CG, respec-
tively. Data are expressed as mean  SEM (eight mice per group). *P  0.05,
**P  0.01, ***P  0.001 as compared to control (WT Naïve). Immunohisto-
chemistry was performed on CG-treated paws of WT (E, H) and Gal-1/
(F, I) mice from the 96-hour time point to examine Gal-9 and Gal-1 expres-
sion in the tissue. WT treated with saline were used as controls (D, G).
Images shown are representative of five mice per group with similar results.
Scale bar, 150 m. J: Cell-free inflammatory exudates recovered from CG
treated paws of WT and Gal-1/ mice, taken from the indicated time pointss of W
ontrol
105/pa
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0
s of WT
11b (PM(24, 48, and 96 hours), were analyzed by Western blotting to determine
soluble Gal-1 and Gal-9 protein levels in the inflamed paw.
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the inflamed paws was performed. Figure 4C-E shows
the marked reduction in immune cell infiltrate after sGal-9
administration, as measured at 96 hours post-CG (that is
72 hours post-Gal-9), when compared to vehicle-treated
mice. In contrast to sGal-9, administration of sGal-1 ther-
apeutically had no effect on the second phase of edema
(data not shown).
There is large body of literature linking galectin biology
to cell apoptosis31; we attempted to determine the de-
gree of apoptosis in the inflamed paws as at least one
potential downstream mechanism responsible for the ef-
fects observed in Gal-1/ mice and also, after sGal-9
administration. Figure 5 reports these results highlighting a
higher degree of apoptosis, measured as expression of the
active form of caspase-3 in Gal-1/mice compared to WT
animals (96-hour tissue sections). Similarly, administration
of sGal-9, according to the therapeutic pharmacological
protocol, markedly incremented the percentage of immune
cells positive for the caspase-3 staining (Figure 5F). Cumu-
lative data, generated with 5 distinct animals, are pre-
sented in Figure 5G: increments varied from a twofold in-
crease in active caspase-3ve cells in Gal-1/mice versus
WT animals to a four-fold increase measured after thera-
peutic treatment with sGal-9.
Finally, we attempted to identify the cells undergoing
apoptosis as a result of treatment with sGal-9. To ad-
dress this we performed double immunofluorescence
staining with anti-CD3 (marker for T cells) with caspase-3.
Figure 6 demonstrates strong co-localization between
anti-CD3 and caspase-3, highlighting T cells as a spe-
cific cell type undergoing apoptosis during this phase of
Figure 4. Administration of sGal-9 produces potent anti-edema effects.
A: sGal-9 was administered intravenously (tail-vein) at three selected doses
(10, 30, 60 g per mouse) 30 minutes before edema induction with CG (right
paw) and saline (left paw) in WT mice. PBS (100 l) was given intravenously
as a control. B: sGal-9 (30 g) or PBS were administered intravenously 24
hours after induction with CG. In all cases, paw volume was assessed by
plethysmography and edema calculated as the difference between CG and
saline injected paws. Data are expressed as mean  SEM of six mice per
treatment. **P  0.01, ***P  0.001 as compared to control (PBS). C–E: Hema-
toxylin-eosin staining of cellular infiltrate was carried out on paws from the
96-hour time point, respectively, following intravenous administration 24 hours
after CG induction with PBS (D) or sGal-9 (30 g) (E). Control (WT Naïve) was
injected with saline alone (C). Images shown are representative of six mice per
group with similar results. Scale bar, 200 m.the edema response.Discussion
The novel findings of this study are that exogenous Gal-1
and -9 may act in concert to limit leukocyte recruitment
and edema formation albeit at different stages of the
inflammatory response. The study also highlights the dif-
fering functions of exogenous galectins and their endog-
enous counterparts.
The edema profiles obtained in both WT and Gal-
1/ mice followed a classical biphasic response as
previously characterized.21 Our finding that adminis-
tration of sGal-1 either as a pretreatment or concomi-
tantly with CG abolished the first phase of edema and
reduced the associated neutrophilic infiltrate corre-
lates with the data of Rabinovich et al12 in which ex-
ogenous Gal-1 ameliorated phospholipase A2-induced
Figure 5. Cleaved caspase-3 expression as a marker of apoptosis. Immuno-
histochemistry was performed for cleaved caspase-3 expression on CG
treated paws from WT (A, B), Gal-1/ (C, D), and WT (E, F) (treated with
sGal-9 30 g, 24 hours after CG induction, see Figure 4B) mice from the
96-hour time point, respectively. Images shown are representative of six mice
per group with similar results. Scale bar  200 m (A, C, E) 50 m (B, D, F).
G: Quantification of caspase-3 positive cells was carried out in a double-
blinded manner, with six fields per section evaluated. *P 0.05, ***P 0.001
as compared to WT.
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shown previously to inhibit neutrophil recruitment in
IL-1 induced peritonitis in mice9 and in vitro using a
human system.11 The lack of any significant effect of
Gal-9 on this first phase of edema suggests the anti-
inflammatory properties of this protein are not through
direct effects on neutrophil recruitment or inhibition of
vascular permeability; indeed scant evidence exists for
a role for Gal-9 in acute models of inflammation that are
neutrophil driven. Data supporting any direct effects of
Gal-9 on the trafficking of cells other than eosinophils is
limited with conflicting evidence on whether it may also
be chemotactic for neutrophils.19,32 The study by
Tsuboi et al19 found Gal-9 to be chemotactic for PMN,
although these PMN recruited by Gal-9 were shown to
be anti-inflammatory PGE2-producing cells which led
to a marked reduction in pro-inflammatory cytokines
produced by recruited MØ. Their anti-inflammatory role
was further emphasized by an enhanced inflammatory
response when mice were rendered neutropenic in this
murine model of the Schwartzman reaction.
Although Gal-1 administration abolished the first phase
of edema it was ineffective against the second phase
suggesting that the two phases are distinct from each
other. Bucci et al33 found that both phases of the re-
sponse were abolished in eNOS/ mice as is the case
for Akt1/ mice34; changes in vascular permeability in-
duced by histamine and bradykinin were also inhibited in
these mice suggesting a direct effect on endothelial per-
meability. In contrast, Gal-1 administration has been
shown to be ineffective against histamine induced-vas-
cular permeability changes suggesting that its effects are
mediated through limiting leukocyte recruitment rather
than a direct effect on the vasculature.12
Against our prediction, during the second phase of the
response the intensity of the edema was significantly
lower in the Gal-1/ mice compared to WT. A lower
degree of edema and leukocyte infiltration in the Gal-1/
mice appears to be at odds with the perceived anti-
inflammatory properties of this protein.13 However, a ma-
Figure 6. Cellular phenotype of caspase-3 positive cells. Double immuno-
fluorescence was performed for cleaved caspase-3 (A) and anti-CD3 (B) on
paw sections treated with sGal-9 30 g, 24 hours after induction with CG.
Panel C shows an overlay of the caspase-3 and anti-CD3 staining with
co-localization indicated by arrowheads. D: DAPI was used as counterstain
for cell nuclei. Scale bar  150 m.jority of studies have focused on the role of the exoge-nous protein with relatively few investigations being
carried out in the Gal-1/ mice. The effectiveness of
Gal-1 in many chronic models of inflammation and auto-
immune disease is largely thought to be mediated
through its ability to induce T-cell apoptosis. On the neu-
trophil, while it does not induce apoptosis Gal-1 induces
PS exposure leading to increased clearance of these
cells suggesting a pro-resolution function for this protein.
Chronic inflammatory models that have been carried out
in the Gal-1/ mice suggest that the endogenous pro-
tein is indeed an important pro-apoptotic signal, at least
for T cells.35 Our hypothesis was that lack of Gal-1 would
exacerbate and prolong this second phase of edema.
The fact that this was not the case suggests that either
other pathways/mediators are at play in these experimen-
tal settings or that the endogenous protein functions in a
different manner to the exogenous one. Indeed, there is a
strong possibility that the differences observed in the
edema response in the Gal-1/ mice may be related to
the role of intracellular rather than extracellular Gal-1. In
the case of Gal-3 it has been shown that extracellular Gal-3
can induce apoptosis in activated T cells36 whereas intra-
cellular Gal-3 can promote T-cell survival.37 A similar dual
functionality may also exist for Gal-1. The potential function
of Gal-1 as a pro-resolving factor in this model is supported,
however, by its increased expression at both gene and
protein level in WT mice at the later time points, with peak
expression correlating with the onset of resolution.
The second phase of edema in this model is reminis-
cent of a delayed-type hypersensitivity reaction22 and is
dependent on iNOS-derived NO. Levels of iNOS were
significantly reduced in Gal-1/ mice compared to WT
mice and this may account for the decreased edema
observed. iNOS expression and activity is significantly
increased in WT mice from 24 hours onward in this
model33,38 and inhibition of iNOS by L-NMMA signifi-
cantly blunts the second phase of edema.22 Although in
the study of Ianaro et al NOS inhibition blunted the edema
response, cellular infiltrate was unaffected. This is in con-
trast to the findings in Gal-1/ mice where both cellular
infiltrate and edema are reduced suggesting a lack of
iNOS induction is unlikely to be the only mechanism in
these mice. As well as a decrease in iNOS expression,
increased levels of transforming growth factor  (TGF)
were detected in Gal-1/ mice. TGF has been shown
to inhibit delayed-type hypersensitivity responses in
mice39 and more specifically to significantly inhibit CG-
induced paw edema in mice40 through inhibition of cyto-
kine generation by draining lymph node cells.
The mRNA expression profiles of Gal-1, Gal-3, and
Gal-9 in the inflamed paws of WT and Gal-1/ mice
revealed a significant increase in Gal-9 gene expression
in the Gal-1/ mice which coincided with the onset of
resolution in these mice. This prompted speculation that
over-expressed Gal-9 may be functioning to reduce in-
flammation in Gal-1/ mice. However, when monitoring
Gal-9 protein expression by immunohistochemistry and
Western blot in both tissue and exudates of inflamed
paws, no apparent differences between phenotypes
were observed. However, Gal-9 protein levels were in-
creased during the inflammatory response and, interest-
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blot of paw exudates, suggesting that Gal-9-expressing
cells are present within the inflamed paws and also that
Gal-9 might be secreted into the extracellular milieu
where it can presumably bind to target cells.
The complete abrogation of the second phase of
edema following therapeutic administration of sGal-9
coupled with the significantly reduced leukocyte infil-
tration may be due to the induction of a subset of
immunosuppressive MØ. A recent study from Arikawa
et al41 demonstrated that Gal-9 significantly sup-
pressed Trichosporon asahii-induced hypersensitivity
pneumonitis in mice through induction of this subset of
myeloid-derived suppressor cells. Expansion of these
suppressor cells resulted in inhibition of T-cell prolifer-
ation and cytokine generation suggesting a possible
mechanism of action for Gal-9 in this model. Gal-9 has
also been found to directly promote TGF-induced
Treg differentiation in vitro18 and sGal-9 increased Treg
expansion in mice in models of CIA18 and contact
hypersensitivity.42
Like Gal-1, Gal-9 is also known to induce apoptosis
of various cell types including T cells14 as well as
fibroblasts.17 We could unveil a strong modulatory
function for exogenous Gal-9 and endogenous Gal-1
(possibly associated with augmented endogenous lev-
els of Gal-9) on the viability of immune cells that had
infiltrated the inflamed paws. Gal-9 induces apoptosis
of Th1 cells through interaction with T-cell immuno-
globulin domain and mucin domain 3 (Tim-3),14 as the
second phase of edema is characterized by a Th1
response40; induction of apoptosis of T cells is a plau-
sible mechanism of action for Gal-9 in this model. Ev-
idence from the double staining performed with anti-
CD3 and caspase-3 revealed co-localization between T
cells and caspase-3, which adds further support to the
notion that Gal-9 is endowed with pro-resolution properties
in this model through induction of leukocyte apoptosis and
increased phagocytic clearance. Clearly, additional studies
will be required not only to reinforce the role of Gal-9 in this
model but also the potential interlink between members of
the galectin family.
The effects of galectins are complex and vary depend-
ing on local concentration, intracellular or extracellular
localization, or differentiation status of the target cell. At
low (30 nmol/L) concentrations Gal-1 inhibits Th1 re-
sponses43 and induces FcRI on monocytes, an effect
that is lost at high concentrations.44 Intracellular Gal-3
protects T cells from apoptosis while the extracellular
protein induces apoptosis (reviewed in 45), while Gal-9
induces maturation of human dendritic cells46 and up-
regulates FcRIIb on macrophages.47 It is therefore not
inconceivable that galectins may cooperate during an
inflammatory response.
In conclusion, loss of Gal-1 leads to an abrogation of
CG induced second-phase edema in the mouse paw.
This reduced inflammatory response is associated with
decreased expression of iNOS and IL-1, in conjunction
with an increased expression of TGF and Gal-9 and
increased apoptosis of infiltrated leukocytes. We wish to
speculate that a Gal-1/Gal-9 cross talk may be operativeduring the course of a resolving model of acute inflam-
mation, a feature that may also have repercussions in
chronic settings, though future studies will address this
hypothesis in detail.
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